Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Kronos Bio Inc chart...

About the Company

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

Exchange

NASDAQ

Website

kronosbio.com

$92M

Total Revenue

99

Employees

$70M

Market Capitalization

-0.58

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $KRON News

Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock?

16h ago, source: Zacks.com on MSN

Kronos Bio, Inc. (KRON) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)

1d ago, source:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kronos Bio (KRON – Research Report), ...

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

6d ago, source:

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; ...

KRON Kronos Bio, Inc.

9d ago, source: Seeking Alpha

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States.

Cancer drug developer Kronos Bio slashes staffing for 2nd time in 4 months

19d ago, source: The Business Journals

See Correction/Clarification at the end of this article. After cutting 19% of its jobs in November, cancer drug developer Kronos Bio Inc. cut 21% Thursday to extend its cash runway to the second ...

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

22d ago, source: Nasdaq

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today ...

Kronos Bio, Inc.: Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

20d ago, source: Finanznachrichten

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for ...

Kronos Bio Inc

1mon ago, source: CNN

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other ...

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

2mon ago, source: Morningstar

and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business ...

Kronos Bio Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...